Faites connaître cette offre !
Reference : UMR7313-MICLAF-007
Workplace : MARSEILLE 13
Date of publication : Friday, November 13, 2020
Type of Contract : FTC Scientist
Contract Period : 24 months
Expected date of employment : 1 February 2021
Proportion of work : Full time
Remuneration : Between 2728,26€ and 3145,68€ gross/month
Desired level of education : PhD
Experience required : 1 to 4 years
The researcher will be hired for 24 months in the framework of the ANR-RUMisBAC project (2021-2025) very recently funded to address one of the main international priorities in the fight against antimicrobial resistance. The overall objective of RUMisBAC, is to take RuminococcinCs bacteriocins one-step further towards their potential use as innovative molecules in the war against antibiotic resistant pathogens.
The researcher's missions will be to investigate the structure-function relationships between RumC peptides and their molecular target to pave the way for the chemical engineering of synthetic RumC-like antimicrobials.
He/She will be i) involved in the RumCs functional characterization and the RumCs-target identification, ii) in charge of the in vitro biological activity evaluation of RumC2-5 isoforms and iii) will be involved in the RumC-like chemical synthesis.
Overall, the applicant must have good expertise in biochemistry, microbiology, microscopy and peptide chemistry.
In detail, the applicant must have skills in:
- anaerobic and pathogens microbiology
- antimicrobial and biological assays
- protein and peptide purification using FPLC and HPLC-preparative technics
- peptide functionalization analysis using HPLC system
Knowledge in molecular biology and peptide synthesis will be an advantage.
Since 2016, the current consortium have developed a close collaboration on RumC bacteriocins across the RUMBA project, supported by the French ANR over a period of 4 years. This project has led to significant results concerning the production of RumC1, its structural organization and its strong antimicrobial activity against priority pathogens identified by public health authorities (Chiumento et al, Science Advances, 2019, Roblin et al., P.N.A.S., 2020)]. The results obtained during the RUMBA project provide a solid basis that now allows us, across the RUMisBAC project, to take the RumCs bacteriocins one-step further towards their potential use as innovative molecules in the war against antibiotic resistant pathogens.
Constraints and risks
The researcher will need to work with pathogen strains in a Level 2 laboratory.
We talk about it on Twitter!